Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Van Dussen, Laura ^a   Biegstraaten, Marieke ^a   Hollak, Carla E M ^a   Dijkgraaf, Marcel G W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ENZYME;

ARTICLE; BONE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DISEASE MANAGEMENT; DRUG COST; ENZYME REPLACEMENT; FOLLOW UP; GAUCHER DISEASE; GAUCHER DISEASE TYPE 1; HEALTH CARE COST; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL CARE; MORTALITY; NETHERLANDS; QUALITY ADJUSTED LIFE YEAR; SPLENECTOMY; TERTIARY CARE CENTER; YEAR FREE OF END ORGAN DAMAGE; ECONOMICS; FEMALE; MALE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; HUMANS; MALE; NETHERLANDS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899586738     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-51     Document Type: Article

References (23)

1. 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE, J Inherit Metab Dis 2008 31 337 349 10.1007/s10545-008-0832-y 18404411
2. Gaucher Disease. Grabowski GA, Petsko GA, Kolodny EH, The Online Metabolic & Molecular Bases of Inherited Disease (Valle D New York: McGraw-Hill, Beaudet AL, Vogelstein B, Kinzler K, Antonarakis SE, Ballabio A, 2010
3. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME, Mol Genet Metab 2002 77 91 98 10.1016/S1096-7192(02)00122-1 12359135 (Pubitemid 35189608)
4. Occurrence of Parkinson's syndrome in type I Gaucher disease. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B, Zimran A, QJM 1996 89 691 694 10.1093/qjmed/89.9.691 8917744 (Pubitemid 26319021)
5. Increased incidence of cancer in adult Gaucher disease in Western Europe. de Fost M, vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, Hollak CE, Blood Cells Mol Dis 2006 36 53 58 10.1016/j.bcmd.2005.08.004 16246599 (Pubitemid 43061488)
6. Increased risk of cancer in patients with Gaucher disease. Shiran A, Brenner B, Laor A, Tatarsky I, Cancer 1993 72 219 224 10.1002/1097- 0142(19930701)72:1<219::AID-CNCR2820720139>3.0.CO;2-Y 8508410 (Pubitemid 23182076)
7. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG, Orphanet J Rare Dis 2013 8 29 10.1186/1750-1172-8-29 23421808
8. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. Clarke JT, Amato D, Deber RB, CMAJ 2001 165 595 596 11563212 (Pubitemid 32881563)
9. Challenges in the economic evaluation of orphan drugs. Drummond MF, Eurohealth 2008 14 16 17
10. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D, Health Technol Assess 2006 10 ii-136
11. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, Klinger L, Hughes D, Waldek S, Lachmann R, Mehta A, Vellodi A, Logan S, Health Technol Assess 2012 16 1 543
12. Analysing clinical studies: principles, practice and pitfalls of Kaplan-Meier plots. Ludbrook J, Royse AG, ANZJ Surg 2008 78 204 210 10.1111/j.1445-2197.2007.04405.x (Pubitemid 351207401)
13. An introduction to Markov modelling for economic evaluation. Briggs A, Sculpher M, Pharmacoeconomics 1998 13 397 409 10.2165/00019053-199813040-00003 10178664 (Pubitemid 28140699)
14. Modeling valuations for EuroQol health states. Dolan P, Med Care 1997 35 1095 1108 10.1097/00005650-199711000-00002 9366889 (Pubitemid 127453463)
15. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ, Health Econ 2006 15 1121 1132 10.1002/hec.1124 16786549 (Pubitemid 44596379)
16. The effect of assessment method and respondent population on utilities elicited for Gaucher disease. Clarke AE, Goldstein MK, Michelson D, Garber AM, Lenert LA, Qual Life Res 1997 6 169 184 9161117 (Pubitemid 27207282)
17. Cost effectiveness of treatment options in advanced breast cancer in the UK. Brown RE, Hutton J, Burrell A, Pharmacoeconomics 2001 19 1091 1102 10.2165/00019053-200119110-00003 11735676 (Pubitemid 33135697)
18. Asselman F, Unit Costs in hospitals Bohn Stafleu van Loghum: Meppel 1 2008
19. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM, Manual for cost research; methods and unitcosts for economic evaluations in health care, actualized version 2010 Diemen: Handleiding voor kostenonderzoek: methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg 2010
20. Need for differential discounting of costs and health effects in cost effectiveness analyses. Brouwer WB, Niessen LW, Postma MJ, Rutten FF, BMJ 2005 331 446 448 10.1136/bmj.331.7514.446 16110075 (Pubitemid 41176388)
21. Enzyme replacement therapy drug holiday: Results from an unexpected shortage of an orphan drug supply in Australia. Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M, Blood Cells Mol Dis 2011 46 1 107 110 10.1016/j.bcmd.2010. 05.002 20684886
22. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Zimran A, Altarescu G, Elstein D, Blood Cells Mol Dis 2011 46 1 111 114 10.1016/j.bcmd.2010.05.001 20542712
23. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Hollak CE, Aerts JM, Ayme S, Manuel J, Orphanet J Rare Dis 2011 6 16 10.1186/1750-1172-6-16 21496291